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Evidence of healing of secondary hyperparathyroidism in chronically
hemodialyzed uremic patients treated with long-term intravenous calcit-
riol. The aim of this study was to assess the effect of a long-term course of
high-dose i.v. pulses of calcitriol (CLT) on hyperparathyroid bone disease
(HBD) and functiohal mass of parathyroid glands of chronically hemo-
dialyzed uremic (CHU) patients. We prospectively studied nine CHU
patients treated with CLT, 30 ng/kg/body wt, i.v., thrice weekly over a
period of eight months. Plasma concentrations of intact parathyroid
hormone (iPTH), bone GLA protein (bGLA) and bone isoenzyme of
alkaline phosphatase (biALP) were sampled throughout. Transiliac bone
biopsies were made before and after the start of CLT therapy. Double
scanning scintigraphy of the neck with 20tTl-99Tc was made before, during
and eight months after the start of the treatment. All patients but one, who
later responded to higher than planned CLT doses, had significant
decreases of plasma iPTH (F = 76; P < 0.0001; ANOVA). The mean
pretreatment value of PTH was 966 160 (mean se) pg/mI and it had
decreased significantly by the first week (T = 2.4, P < 0.04), and had fallen
an average of 80% by the 35th week. Ionized plasma calcium concentra-
tion was 1.19 .01 mmol/Iiter which rose significantly (F = 13,5; P <
0.0001) by the 14th week to maximal peak levels, averaging 1.34 .02
mmol/liter. Changes in biALP were parallel to those of iPTH, while bGLA
tended to increase immediately after the start of the therapy and to
significantly decrease thereafter (T = 3.2; P < 0.01). There were signifi-
cant decreases in all histomorphometric indices of HBD: the osteoid
volume from 12 1.8 to 4.8 0.5% (P < 0.001), the osteoid surface from
45.7 3.2 to 27 5.2% (P < 0.001), the osteoblastic surface from 11.8
1.7 to 4.8 1.08% (P < 0.001), the eroded surface from 6.6 1.2 to 4.3
0.9 (P < 0.002), and the osteoclast surface from 2.2 0.3 to 1.2 0.3%(P < 0.009); there was even renornialization in some individual patients.
The bone formation rate was measured in six of the nine patients and was
found to be lowered in all subjects who had had significant PTH decreases.
The median of intensity of 201T1 uptake before therapy scored 7.8 (range
4 to 9.2) arbitrary visual units and decreased significantly (P < 0.001;
Wilcoxon test) to 0.4 (0 to 8.25) after eight months of CLT treatment,
suggesting significant decreases of the mass of the parathyroid glands.
Thus, this study demonstrates that long-term therapy with high-dose i.v.
pulses of CLT in CHU with proven HBD is able to consistently decrease
their circulating iPTH to levels comparable with those of subjects with
mild or no HBD and also to decrease the functional mass of their
parathyroid glands. Further studies will ascertain what dose of CLT is
required to maintain this state of euparathyroidism once the hyperpara-
thyroidism has been reversed.
Secondary hyperparathyroidism of chronic uremic patients is a
severe endocrine disorder in which progressive enlargement of
parathyroid glands results in excess parathyroid hormone (PTH)
secretion, with an unwanted osteodestructive disease of the bone
[1]. For several years the therapeutic approach to this syndrome
has included restriction of phosphate intake, avoidance of nega-
tive external calcium balance and oral supplementation of syn-
thetic analogues of calcitriol (CLT) [1, 21, since hyperphos-
phatemia, hypocalcemia and 1,25 (OH) D3 deficiency were
thought to promote parathyroid overgrowth with its attendant
PTH oversecretion [1, 31. This combined therapeutic regimen,
however, is often hard to handle as it is fraught with the difficulty
of supplying CLT in doses large enough to lessen the PTH
oversecretion without inducing excessive CLT-mediated intestinal
absorption of calcium and phosphate, which could expose the
patient to threatening hypercalcemia and extraosseous calcium-
phosphate salts precipitation [4]. Some years ago, Slatopoisky et a!
intermittently administered high doses of CLT Lv. and proved
these to be effective in inducing quick and consistent decreases in
plasma PTH levels while avoiding excessive plasma calcium and
phosphate increases [51. Since then, other studies have been
reported [6—9] which confirmed and extended these findings.
To date it is not known to what extent the PTH of uremic
patients must be lowered, nor is it completely clear whether i.v.
CLT treatment, in addition to lowering plasma PTH, also consid-
erably improves the PTH-mediated osseous lesions and reduces
the mass of parathyroid glands. We therefore undertook a longi-
tudinal prospective study in a group of uremic patients with
secondary hyperparathyroidism who were treated with i.v. CLT
for eight months. Plasma PTh (iPTH), bone GLA protein
(bGLA) and bone isoenzyme of alkaline phosphatase (b1ALP)
were sampled throughout. Functional parathyroid mass was as-
sessed serially by double scanning scintigraphy, while bone histo-
morphometry by transiliac bone biopsy was evaluated before the
start and eight months after the beginning of i.v. CLT therapy.
Methods
Patients
Subjects were selected from a cohort of nearly 130 subjects
currently treated at the Dialysis Unit of our Division of Nephrol-
ogy. Exclusion criteria were: previous kidney grafting and/or
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prolonged use of steroids, past assumption of large amounts of
aluminum salts, positive deferoxamine test indicating aluminum
overload, average plasma total calcium (TCa) concentration
exceeding 10.5 mg/dl and serum phosphate (SPhOS) higher than 6.5
mg/dl. Inclusion criteria were: average plasma iPTH concentra-
tion 6 times the upper normal limit, total ALP (TALP) exceed-
ing the upper normal value by 50%, and radiological findings of
hyperparathyroid bone disease (HBD). Of the twelve patients
initially selected following these criteria, one was given a trans-
plant, one was switched to peritoneal dialysis and the other died
from myocardial infarction. The nine patients who were finally
selected were four men and five women, aged 33 to 70 years. One
of them had been parathyroidectomized two years before. Sub-
jects had been on hemodialysis for 4 to 11 years and were dialyzed
with bicarbonate three times a week against a dialysis bath with a
calcium concentration of 3.5 mEq/liter. All were taking calcium
acetate as the phosphate binder and had been on standard oral
CLT, 0.25 daily or 0.5 jg every other day, for at least four years.
None of them took cardiovascular or anticonvulsivant drugs. No
patient took oral CLT treatment for at least three months prior to
the study. During this period, serial measurements of some basal
biochemical parameters were made. Furthermore, all subjects had
their dietary intakes of calcium and phosphate formally assessed
by dietary interviews and two-day diet diaries, with weighing of the
foods. During the same period the subjects were switched to a
dialysis bath containing 3 mEqlliter of calcium. Transiliac biopsy
of the bone, after informed consent was given, and scintigraphy of
parathyroid glands were made within ten days before starting i.v.
CLT treatment. CLT was started at a dose of 30 nglkg/body wt
(corresponding to a total dose of 2.1 tg for a 70kg subject), thrice
weekly, at the end of each hemodialysis session. Plasma samples
for ionized calcium (ICa), TCa, SPhOS, TALP and iPTH were
drawn weekly, while bGLA and biALP were sampled about every
45 days. Parathyroid imagings were repeated after three to four
months and after eight months, while bone biopsies were repeated
eight months after the start of CLT therapy. During the study a
series of criteria to prevent the onset of both hypercalcemia and
hyperphosphatemia were used. As soon as predialysis ICa reached
a value  1.35 mmol/liter, patients were switched to dialysis baths
with 2.5 mEq/liter of calcium. On persistence of hypercalcemia
the CLT dose was halved for a week, and then was discontinued
until the ICa reached a value 1.30 mmollliter, at which time the
initial dose was resumed. Following the onset of hyperphos-
phatemia ( 6 mg/dl), oral calcium acetate was increased up to a
maximum of 6 g a day and, when necessary, aluminum hydroxide,
up to a maximum of 2 g a day was allowed for only ten days. If
these interventions were ineffective CLT was stopped.
Assays and measurements
The intact (1-84) PTH was measured by an IRMA (INCSTAR
Corp., Stillwater, Minnesota, USA). The normal range in our
laboratory is from 10 to 55 pg/mI. Intra- and interassay coefficients
of variation were 3.5 and 6.8%. Bone Gla protein was measured
by a radioimmunoassay (CIS; Bio International, France); the
normal range is 1 to 14 g/dl, intraassay variation 5%, interassay
variation 6.8%. The biALP was determined by a photometric
assay, according to the method of Rosalky and Foo [101; normal
values in our laboratory range from 20 to 150 lU/liter. Serum
ionized calcium was determined by an ICA 1 ionized calcium
analyzer (Radiometer A/S, Copenhagen, Denmark). Serum alu-
minum was measured by fiameless atomic absorption spectropho-
tometiy, while TCa, Phos, and TALP were measured by routine
laboratory autoanalyzers. Transiliac bone samples were taken five
days after completing double bone labeling (2 days on, 16 days off,
2 days on demethyl-chlortetracycline, 600 mg a day) with a
Jamshidi trocar with an internal diameter of 4 mm. The specimens
were processed according to procedures previously reported [11],
which also included evaluation of bone aluminum deposits by the
aurin tricarboxylic acid method [12]. Quantitative histological
analysis was accomplished with the aid of a semiautomatic image
analyzer (Videoplan-Kontron, MUnchen, Germany) and the his-
tomorphometric parameters expressed according to the standard-
ized nomenclature [13], without knowledge of the corresponding
biochemical and clinical findings. The static indices of bone
formation considered were: the osteoid volume (OV/BV%),
expressed as a percent of the trabecular bone volume; the osteoid
surface (OS/BS%) expressed as a percent of the trabecular bone
surface; the osteoblastic surface (ObS/BS%), as a percent of
trabecular bone surface osteoid lined by cuboidal osteoblasts and
the osteoid thickness in m. As static indices representative of
bone resorption, we measured: the eroded surface (ES/BS%),
which is the percent of trabecular bone surface with Howship
lacunae; the osteoclast surface (Oc.S/BS%), which is the fraction
of trabecular bone surface lined by osteoclasts and the number of
osteoclasts per m2 of tissue section, The dynamic parameter of
bone formation (BFR) in tm3/tm2/day, was calculated by multi-
plying the measured rate of mineral apposition by the total
tetracycline-labeled mineralizing surface. For comparisons with
normal values, data for static parameters were collected from
necroscopic bone samples of fifty people dying suddenly or in
violent accidents, matched for sex and age and coming from to the
same geographical area of our subject study group. Parathyroid
masses were localized by Thallium-201 (201T1) and Technetium
99m (99TC) subtraction scintigraphy [14], with data acquired by a
gamma-camera with collimator connected to an on-line computer.
The scannings collected were read thrice by a very experienced
operator, who was unaware of the subject's identity, the order in
which the scintiscans had been performed, or when the scinti-
maps had been obtained from the same subject.
Calculation and statistics
The intensity of the 201T1 uptake by the parathyroid glands was
evaluated by averaging three consecutive estimates of the reader,
who labeled an ungraduated visual analogic scales from arbitrary
units (AU) [15] scoring from 0 (no uptake) to 10 (very high
uptake). To assess the reproducibility of these readings, we
calculated the percentage differences between the middle value
and the lower and the higher values of each reading. These
percentage differences were averaged, and the standard devia-
tions of this average and the 95% confidence limits (mean 2 SD)
were calculated. Changes in 201'fl uptake (positive or negative)
exceeding these values were considered to not be random vari-
ability but to be significant.
Results are presented as means SE. Comparisons for repeated
measures were made by the analysis of variance (ANOVA). When
the F test was significant, then the Student's I-test was used for
comparison of two groups. Comparisons between two means,
when there was skewed distribution of the data, were made by the
Wilcoxon non-parametric rank test. The statistical significance of
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Table 1. Effects of i.v. CLT therapy (30 ng/kg/body wt, thrice weekly) for 8 months, on total serum calcium (TCA) and phosphate (SphO), total
alkaline phosphatase (TALP), bone isoenzyme of alkaline phosphatase (biALP) and bone GLA protein (bGLA) measured serially, in eight dialyzed
uremics with hyperparathyroid bone disease
0 day 15 days 30 days 45 days 60 days 75 days 90 days 105 days
TCa 9.6±0.1 9.4±0.1 9.5±0.1 9,7±0.1 9.7±0.1 9.7±0.1 9.8±0.1 9,6±0.1
mg/dl
SphO 5.4±0.3 4.5±0.3 5.2±0.3 5.1±0.2 5.3±0.3 5.7±0.2 5.3±0,2 5.2±0.3
mgldl
TALP 781 146 751 172 634 156 508 144 444 136 380 124 287 80 271 175
lU/liter
bIALP 680 164 — — 445 94 — — 201 8o
lU/liter
bGLA 68 4.3 — — 68.3 8.3 — — 107 20 —
p.g/dl
associations between two variables was assessed by calculating
Spearman's rank correlation coefficient (Rs).
Results
The average values for some biochemical parameters measured
during the three month period when off oral CLT treatment were:
plasma PTH 839 100 pg/mI, TCa 9.2 0.05 mg/dl, ICa 1.20
0.02 mmol/liter, SphO 5.2 0.19 mg/dl, TAP 619 69 lU/liter,
and plasma aluminum 15 3 pg/liter. The assessed dietary
intakes of calcium and phosphate were 504 50 mg/day (range
247 to 742) and 1073 87 mg/day (range 700 to 1543), respec-
tively. The mean daily intake of calcium acetate during the eight
month study period was 5.2 0.18 g (range 4.5 to 6). To prevent
the onset of overt hypercalcemia, six of the nine patients had to be
switched to low-calcium dialysis baths two to six months after
starting i.v. CLT therapy. To prevent hyperphosphatemia, short-
term courses of low doses of aluminum hydroxide were required
by all subjects. The number of aluminum administration cycles
ranged from 1 to 9. Intravenous CLT was withheld for seven of
nine patients for a period of one to four weeks. At the end of the
study period, the calculated weekly i.v. CLT dose for each patient
averaged 5.4 0.2 j.g (3.9 to 6 j.g).
One patient did not respond to the planned i.v. CLT; however,
he did respond eight months later after stepped increases in the
dose (see below). Sequential changes in iPTH concentrations and
in ICa in the eight patients who responded earlier are shown in
Figure 1. The mean value of iPTH soon after oral CLT was
stopped was 808 98 pg/mI and tended to increase, but insignif-
icantly, during the following three months. The baseline iPTH
immediately before the start of i.v. CLT therapy was 966 160
pg/ml (416 to 1727) and it decreased significantly (F = 76; P <
0.0001; ANOVA) and continuously thereafter. Plasma concentra-
tions of the hormone declined from the first week (T = 2.4; P
0.04) to the 22th week, and then flattened off, reaching a final level
of 153 38 pg/ml (60 to 332). The average pretreatment value for
ICa was normal (1.19 0.01 mmollliter, normal range: 1.15 to
1.30 mmol/liter). After the start of i.v. CLT therapy, ICa levels
fluctuated slightly within normal values, then tended to rise to a
level significantly higher than baseline after week 14 (T = 2.28;
P < 0.05). From this time onward, ICa continued to rise but
average peak levels never exceeded 1.34 mmollliter. Table 1
reports the changes of plasma concentrations of the other bio-
chemical and humoral parameters that were sampled throughout
the study. There were significant decreases in plasma TALP
concentrations (F = 109; P < 0.0001; ANOVA) by the third week
(T = 2.9; P < 0.02) and in biALP by the seventh week, the final
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Fig. 1. Weekly values (mean SE) forplasma
concentrations of intact parathyroid hormone
(0) and ionized calcium (U) in eight
hemodialyzed uremic patients, before and after
the start (arrow) of i.v. therapy with calcitriol,
30 rig/kg/body wt thrice weekly, for 8 months.
Asterisks indicate significance (*P < 0.05; **P
<0.01) versus time 0. Dashed area is the
normal iPTH range.
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Table 1. Continued
120 days 135 days 150 days 165 days 180 days 195 days 210 days 225 days 240 days
TCa 10±0.2 10.1±0.1 lo.1±o.la 10.5±0.la 10.5±0.2 10.4±0.2a 10.4±0.2' 10.4±0.la 10.1±0.1
mgldl
S,0, 5.4± 0.5 5.3±0.3 5.3±0.3 5.8 ±0.3 5.2±0.4 5.7±0.3 5.4±0.3 5±0.1
mg/dl
TALP 256 74 255 8T 232 81" 224 60 227 60" 222 46" 215 51" 186 29" 192 32"
lU/liter
biALP 130 62" — 117 48 — — 95 32" — 80 18'
lU/liter
bGLA 48 7.8" — — 44 7" — — 41 a 39 6.8a
pg/dl
Data are means SE.
a Significance versus the basal levels
values being 105 to 372 and 33 to 195 lU/liter. Bone GLA protein
concentrations measured nearly 90 days after the start of i.v. CLT
were found to be higher, although insignificantly, than the base-
line because there were opposite changes in plasma concentra-
tions of the protein in the group, since it tended to rise in five
patients and decrease in the others (data not shown). From this
time onward, however, there were concordant decreases in bGLA
in the whole group, so that the changes became significant by the
four month (T = 3.2; P < 0.01). Final values of bGLA of all
subjects (range 23 to 84 g/dl) remained over the upper normal
limit of the protein assay in our laboratory. The TCa remained
nearly unvaried until the nineteenth week then started to increase
significantly (T = 2.6; P = 0.03), remaining higher than the basal
level. The average baseline SphO. concentration was higher than
normal and remained essentially unchanged thereafter.
Figure 2 shows the patterns of iPTFI, biALP and ICA in the
subject who did not respond to the standard treatment. Neither
his iPTH nor his biALP decreased over eight months on i.v. CLT
treatment. It was therefore decided to increase his i.v. CLT dose
to 40 ng/kg body wt and then to 50 ng/kg body wt, thrice a week.
As can be seen, this latter dose resulted in sharp decreases of both
iPTH and biALP concentrations, without inducing any consider-
able increase in ICA plasma concentration.
Analytical details of the most important histomorphometric
parameters measured before and eight months after starting the
i.v. CLT therapy are given in Table 2. Three of nine patients
showed no evidence of positive tetracycline-labeled surfaces in the
examination of the first bone biopsy. Scrutiny of each individual
case revealed that two patients did not closely adhere to the
advices for correct tetracycline assumption, while the third patient
admitted he did not take the drug. Static histomorphometric
indices of bone formation and resorbtion were all far above the
upper limit of the range for the control subjects (Table 2). After
eight months of treatment, with the exception of the patient who
did not respond to the therapy, these indices became lower in all
subjects, to complete normalization in some of them. These
changes were all statistically significant when the "non-responder"
patient was excluded from the analysis. Also significant were the
changes in other parameters of the histomorphometric examina-
tion, including the osteoid thickness 14 0.6 m after therapy
compared to 20.5 0.8 (T = 11.7; P = 0.001), and the number of
osteoclasts per m3 of tissue section (0.9 0.2 vs. 2.2 0.5; T =
3.6; P < 0.008). Overall, changes in static histomorphometric
parameters were parallel to those in plasma iPTH (Figs. 3 and 4),
TALP and biALP (data not shown). The average BFR before i.v.
CLT was 0.43 0.1 m3/m2/day. It decreased in all subjects who
30 ng 40 ng 50 ng/kg/body wt
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Fig. 2. Plasma intact parathyroid hormone (•)
and alkaline phosphatase bone isoenzyme (A)
and ionized calcium (•) in a hemodialyzed
uremic patient given increasing doses of i. v.
calcitriol therapy thrice weekly.
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PTH, pg/mi
Fig. 3. Plasma concentrations of intact parathyroid hormone and percent
osteoid volume of the iliac bone for eight hemodialyzed uremic patients before(•) and after (0) 8 months of pulsed high-dose Lv. CLT therapy. PTH is
significantly correlated with the corresponding OV/BV (%) values (Spear-
man's r = 0.912; P < 0.0001). The dashed area is the range of osteoid
volume for fifty sex- and age-matched control subjects.
responded to the therapy (0.16 0.1) and rose in the non-
responder patient (Table 2). Stainable aluminum bone deposits
were not seen either before or after treatment.
Fourteen putative parathyroid glands were identified by 201'fl
99TC subtraction scintigraphy of the neck in eight patients, while no
glands were found in the parathyroidectomized patient (Table 3).
The calculated intra-reading variation for this series of basal readings
was 1.18 11%. Thus, the intrinsic variability of each reading was
considered to range from —21 to +23% (mean 2 SD).
After eight months of therapy both the number and the
intensity of uptake remained almost the same in three patients,
including the one who did not respond to the therapy, while the
other had complete disappearance of the glands or great and
significant attenuation of the uptake (Table 3).
Discussion
Treatment of the osteodystrophic uremic syndrome includes
control of serum calcium and phosphate and administration of
PTH, pg/mi
Fig. 4. Plasma concentrations of intact parathyroid hormone and percent of
iliac bone suiface covered ly osteociasts in eight hemodialyzed uremic
patients, before (S) and after (0) 8 months of pulsed high-doses Lv. CLT
therapy. PTH is significantly correlated with the corresponding Oc.S/BS
(%) values (Spearman's r = 0.715; P = 0.002). The dashed area is the
range of osteoclast surface for fifty sex- and age-matched control subjects.
CLT analogues [1, 3]. The mainstay of the therapy, however, is
CLT supplementation, since maintenance of normal serum cal-
cium and phosphate concentration by oral calcium loads and
intestinal binding of dietary phosphate do not prevent PTH
oversecretion [16]. For many years, CLT analogues have been
administered by continuous daily oral assumption [4]. This
method of administration, although frequently effective in both
lowering plasma PTH and in improving bone lesions [17], is often
hindered by the onset of hypercalcemia [1, 4]. In 1981, Madsen,
Olgaard and Ladefoged demonstrated that circulating PTH levels
of patients with acute renal failure could be decreased within
hours following repeated i.v. injections of high doses of CLT,
without any measurable increases in plasma calcium concentra-
tions [18]. Some years later, Slatopoisky et al gave i.v. CLT
boluses three times a week to a group of chronic uremic patients,
and observed considerable decrease of their plasma PTH concen-
trations before the serum calcium changed [5]. These findings,
besides revealing an inhibitory effect of CLT on PTH secretion
Table 2. Analytical details of some histomorphometric parameters in transiliac bone biopsies, for nine dialyzed uremic patients, before (b) and
eight months after (a) the start of i.v. therapy with calcitriol (30 ng/kg/body wt)
BFR/BS
OV/BV
%
b
Ob.S./BS
%
a
ES/BS
%
Oc.S/BS
%
mz34un2/
day
b a
MAR
pin/day
b ab a b aPatient b a
1 24.9 7.4 21.1 10.5 15.4 10.1 3.8 3.5 0.9 0.26 1.63 0.88
2 9.2 3.82 11.3 1.48 4,4 2,3 2,07 0.8 0.35 0.06 1.18 0.7
3 13.7 5.3 7.1 4.1 4.8 3.4 1.45 0.78 0.17 0.12 0.61 0.73
4 12.2 5.8 13.6 7.9 5.3 3.5 1.66 0.96 0.25 0.21 0.8 1.04
5 11.7 5.1 7.2 5.8 5.1 3.7 1.27 1.32 0.48 0.19 1.14 0.81
6 9.6 2.6 15.6 4.1 5.07 2.7 2.71 0.58 — 0.13 — 0.77
7 9.7 2.8 7.8 2.9 6.9 6.3 2.31 1.27 — — — —
8 9.7 5.9 11.1 2.1 6.3 2.6 3.2 1.04 — 0.12 — 0.8
9 4.5 12.3 11.8 23.6 5.7 8.1 5.44 8.5 0.4 0.86 0.8 2
Mean±sn 12±1.8 4.8±0.5k' 11.8±1 4.8±1.la 6.6±1.2 4.3±0.9a 2.2±0.3 1.2±0.3a
n.r. 0.06—4.04 0—2.75 0,09—4.59 0—0.57
Means values refer to patients n.1 to n.8. Ranges (n.r.) for static indices of fifty sex- and age-matched normal subjects are also indicated.
Significance (after vs. before, with P at least < 0.009)
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Table 3. The number of putative parathyroid glands detected by 201T1-
99Tc subtraction scintigraphy with the corresponding scores (in arbitrary
units) of 201T1 uptake, in eight hemodialyzed uremic patients, before,
during and 8 months after the start of pulsed high-dose i.v.
calcitriol therapy
N
Patient Glands Basal Third month Eighth month
1 1 5.1 6.6 0
2 2 4 4 0
3 3a
3b
9
9.2
8
8.9
7.15
8.25
4 4a
4b
8.2
8.2
7.9
7.4
7.4
7
5 5a
5b
5c
7.8
6.35
4.8
4.4
1.3
0
0
0.4
0
6 6a
6b
6.9
7.9
5
5
0
0
7 7 6 6.8 6.6
8 8a
8b
8.9
8.8
3.5
0
1.15
0.85
Range 4—9.2 0—8.9 0—8.25
Median 7.8 5 Q•4
Subject number 3 did not show consistent iPTH decrease following 8
months CLT therapy.
a SignificanceP < 0.001 (with the Wilcoxon non-parametric test) versus
the basal values
independent of changes in plasma calcium, also opened the way to
a new method to administer CLT therapy by which PTH inhibi-
tion could be obtained at lower risk of hazardous hypercalcemia.
As a matter of fact, many papers appearing thereafter have
confirmed that intermittent high doses of CLT given either i.v.
[6—9] or as oral boluses [19] induce large decreases in plasma PTH
with only minor changes in plasma calcium concentrations. Most
of these studies, however, were aimed at ascertaining whether and
to what extent plasma iPTH could be lowered, or to elucidate the
effect of this type of therapy on the reciprocal relationships
between changes in ambient calcium and parathyroid hormone
release. No studies were specifically aimed at ascertaining to what
extent plasma iPTH must be lowered in order to induce consid-
erable improvement in bone lesions and to possibly reduce the
parathyroid functional mass. We, therefore, prospectively studied
a group of chronically hemodialyzed uremic patients already
deemed to have secondary hyperparathyroidism refractory to
conventional continuous daily oral CLT therapy. The main crite-
rion for inclusion in the study was an iPTH concentration  6
times the upper normal value, because it had already been
observed that concentrations of intact PTH above this limit are
representative of an underlying severe HBD [201. Before entering
the study the subjects were also screened to exclude occult body
aluminum overload, since decreases of circulating iPTH in these
subjects could theoretically precipitate an aluminum-associated
bone disease [21]. All of the patients enrolled had normal plasma
calcium and "controlled" serum phosphate concentrations, but
either their iPTH or TALP and biALP concentrations were
greatly elevated, indicating a severe degree of HBD.
While it seems clear that intermittent peak increases in plasma
CLT concentration are more effective in decreasing plasma iPTH,
than the same amount of CLT given continuously over a longer
time period [22], there is still debate as to whether oral or i.v.
boluses are to be preferred [23]. Theoretically, the i.v. adminis-
tration would have the advantage of avoiding excess hypercalce-
mia resulting from overexposure of the intestinal CLT cell
receptors to CLT, and of achieving high peak increases with
occupancy of parathyroid CLT receptors by circumventing the
hepatic CLT degradation [4, 23, 24].
In our study, we planned to administer the drug i.v., since it has
the obvious clinical advantage of being strictly supervised [23].
Problems of compliance or correct adherence to the scheduled
prescription may be causes of therapeutic failure [23, 25] even in
patients like ours, who were willing to adhere to the medical
prescription. The CLT dose we used was 2.1 g/70 kg/body wt,
since in the experience of one of us (D.R.) a dose lower than this
did not result in overall PTH and TALP decreases in a large
dialysis population group [261. Such a high dose of CLT, however,
might cause hypercalcemia, which would hinder continuing the
CLT therapy. This was why we used a phosphate chelating
regimen, in which calcium acetate was combined with intermittent
administration of aluminum hydroxide. In a previous study,
administration of doses of aluminum hydroxide up to 30 mg/kg
over one year did not significantly increase bone aluminum
content in a group of young uremic patients treated with oral CLT
[27]. In our patients, the cumulative daily intake of aluminum
hydroxide over the entire study period ranged from 70 to 700 mg,
corresponding to doses of ito 10 mg/kg for a 70 kg subject. Thus,
even though one cannot disregard the potentially toxic effects of
aluminum-containing phosphate binders, we feel it is unlikely that
combined therapy with i.v. CLT and aluminum hydroxide in doses
as low as those we have used might have had significant adverse
effects in adult uremics. In our subjects, with the exception of the
patient who later "responded" to higher doses, the average
planned CLT dose administered i.v. thrice weekly over an eight
month period caused a sharp decrease in iPTH from the first week
and continuing until the fourteenth week. At this time the average
decrease in iPTH was 61%, with no significant changes in either
Ica or TCa in the meantime. From this time onwards, ICa
increased slightly and PTH decreased further to an average of less
23%. Prevention of hypercalcemia with low calcium dialysis bath
[28] and chelation of phosphate with combined calcium acetate
and low-dose aluminum hydroxide [29] allowed us to administer a
total CLT dose probably higher than those in previously reported
studies. This is the likely explanation for such an impressive
calcium independent PTH-inhibitory effect of i.v. CLT, which to
our knowledge is one of the largest so far reported. These findings
are strong support for previous contentions of the outstanding
role of CLT deficiency in inducing pathologic PTH secretion of
chronic uremic patients [5, 6, 24], Parathyroid cells have ste-
reospecific receptors for CLT similar to those found in intestine
and bone [30]. CLT regulates the density of its receptors by
increasing the expression of the CLT mRNA receptors gene.
Occupancy of these receptors by the sterol leads to selective
decrease of PTH mRNA synthesis [30]. Therefore, chronic defi-
ciency of CLT due to defective production by the failing kidney
might result in increased PTH synthesis, since low levels of CLT
are delivered in proximity to the parathyroid receptors and the
glandular density of these receptors is decreased. As a matter of
fact, in chronic uremia, CLT receptors have been found to be
lowered [31], so that supraphysiological levels of circulating CLT
were required to overcome the abnormal PTH mRNA synthesis in
uremic rats [32].
In chronically hemodialyzed uremic patients with long lasting
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secondary hyperparathyroidism, both nodular and diffuse-type
parathyroid hyperplasia have been described [33]. The nodular
tissue consists of clusters of actively proliferating parathyroid cells
and gland weight is heavier and density of CLT receptors is lower
than for the diffuse-type hyperplastic tissue [33]. In our study, one
patient had a very high circulating iPTH level which was not
lowered until nearly double the initial CLT dose was used (Fig. 2).
In this subject, the changes in plasma ICa were quite similar to
those already observed in the responder patients as a whole, so
that a major contribution of ICa to induction of such a sharp
decrease in iPTH concentration can be excluded. Lesser density of
parathyroid CLT receptors in this patient is a more likely expla-
nation for the initial glandular resistance to the PTH-lowering
property of the sterol, which became evident only when very high
doses were given.
Whatever the mechanism, to a clinician who is interested in the
overall therapeutic effect, it is important to know whether the
administration of pharmacological doses of CLT not only lower
circulating PTH but are also able to improve its untoward osseous
effects, Classically described histological features of HBD include
increased numbers of osteoblasts, appearance of woven osteoid
and increase in bone formation rate [34]. In our patients, all static
indices of bone formation and bone resorption were far above the
upper limits of our normal control group. Furthermore, in those
subjects who had positive tetracycline-labeled surfaces, the calcu-
lated BFR was found to be higher than the upper limit already
reported for a normal population [35]. Eight months of ix. CLT
therapy caused all these indices to decrease in each patient, with
normalization of some parameters in some of them. These
findings are in keeping with those already reported in the only
study we know of the osseous effects of long-term i.v. CLT therapy
in chronically dialyzed uremics [7].
However, there are some differences between our study and
that previous study which deserve some comment. In the study of
Andress et al [7], there was a significant decrease of the osteoid
surface covered by osteoblasts, no change in the amount of
osteoid tissue and a worsening of osteoclastosis in four of eleven
patients. Furthermore, there was no significant decrease in PTH,
as measured by the C-terminal assay, while the alkaline phos-
phatase, although significantly lowered, did not normalize. These
findings might cast some doubt as to whether this therapy was
indeed completely successful in those patients [36]. In our study
we used a low-calcium dialysate bath to prevent the onset of
hypercalcemia that would have hindered our efforts to administer
an i.v. dose of CLT as large as possible. In the study of Andress et
al, higher concentrations of calcium in the dialysate were used and
there were frequent episodes of hypercalcemia. Thus it is possible
that in that study, in the face of recurrent hypercalcemia, that
average doses of CLT lower than ours were infused, which
accounted for the apparently less successful therapy of those
patients. In our patients, to be certain that bone findings did
indeed reflect bone PTH activity, we attempted to eliminate such
confounding variables as body aluminum overload [21, 34]. In the
study of Andress et al, BFR was decreased in all patients,
although some static osseous indices still indicated the existence
of high PTH bone activity [7]. Some patients of Andress et al,
however, had signs of worsening bone aluminum retention during
i.v. CLT therapy. Thus, it cannot be excluded that in those
patients some degree of bone aluminum deposition might have
contributed to inducing a deceleration of the bone formation rate
[21, 34, 36].
Both bGLA protein and alkaline phosphatase are increased in
chronic uremic patients with HBD reflecting pathologically high
bone turnover rate [34]. In keeping with both bone findings and
iPTH levels, both proteins were greatly raised in our subjects.
Intravenous CLT therapy, along with decreases in iPTH concen-
trations and improvement of HBD lesions, also caused parallel
decreases of both biALP and TALP to values within normal
limits, These findings demonstrate that either biALP and TALP,
which also includes the liver component of the enzyme, might be
a useful non-invasive marker for monitoring HBD lesions during
long-term CLT therapy, provided underlying chronic liver dis-
eases are excluded. In our patients, bOLA protein showed a
biphasic response, with an early increase soon after the start of i.v.
CLT therapy followed by a decrease some time later. These
findings reconcile previous studies in which increases after short-
term CLT courses [37] or decreases after longer CLT treatment
[38] were reported. Probably the early increase mainly reflects the
direct stimulatory effects of the sterol on the bone, while the later
decrease is a reflections of lessened bone PTH overactivity [37,
38]. In our patients, bGLA protein, although decreased, did not
normalize. In dialyzed patients, however, bULA protein might be
raised due to either increased production from high bone turn-
over or to decreased plasma clearance owing to lack of renal
excretion [34, 38]. Either chronic hypocalcemia or decreased
circulating CLT levels could be factors involved in proliferation of
parathyroid cells in chronic uremia [30]. In addition to the
PTH-lowering effect, therefore, chronic CLT administration could
also reduce the size of already enlarged parathyroid glands. In a
previous study, intraperitoneal CLT administration for four to six
weeks resulted in enhanced cellular apoptosis of the parathyroids
of chronically uremic rats [39]. It is still controversial whether
CLT pulsed therapy might result in regression of parathyroid
hyperplasia in chronic uremic humans. In fact, both decreased
[40] and unchanged [41] sizes of ultrasonographically measured
glands have been found after short [40] or long term [41] therapy
with equivalent doses of pulsed high dose oral CLT. Adequate
imaging of the parathyroid by ultrasonography is critically depen-
dent on the operator's skill and both false-positive and false-
negative results can be due to concomitant thyroid diseases [42].
Furthermore, repeated evaluation of the glands, such as those
made in the above studies, might not reveal changes in echo-
graphically measured gland sizes when apoptotic cells have been
replaced by fibrotic tissue. In the present study, to circumvent
these shortcomings, we attempted to evaluate the mass of para-
thyroid glands by 201Tl-99Tc subtraction scintigraphy. Since thal-
lium behaves biologically like potassium [43], high 2OFuptake
would imply a high density of biologically active cells. Thus, the
results in this study, are not readily comparable to those using
echography, by which the "physical" rather than the "functional"
mass of parathyroids is explored.
In previous experimental studies, treatment of rats with high
CLT doses before performing subtotal nephrectomy prevented
the development of parathyroid hyperplasia, while ten days of this
treatment started three weeks after subnephrectomy did not
reduce the weight of the glands that had become hyperplastic in
the meantime [44]. In the present study the parathyroid 201Tl
uptake was attenuated three to four months after starting i.v. CLT
treatment, and was significantly lowered eight months after the
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treatment began. Thus, this lessened uptake of the tracer in our
patients could be due to either a generalized decrease of the
biological activity of their parathyroid cells or to a reduction of
their absolute numbers. From these findings it can be inferred that
high doses of CLT might lead to regression of parathyroid cellular
hyperplasia, provided enough time is allowed to elapse after
starting the therapy.
To conclude, in the present study, long-term treatment with
high i.v. CLT doses of a group of hemodialyzed uremics with
proven secondary hyperparathyroidism resulted in decreases of
iPTH to levels which are comparable to those of patients with
mild or no HBD [20]. Furthermore, the histomorphometric
indices of HBD improved in all patients, with normalization in
some of them, while biALP nearly normalized. Finally, imaging
studies of the parathyroids gave evidence of reduction of the
functional mass of the glands. Taken together, these findings are
evidence of healing of HBD in our subjects. Careful monitoring of
these patients is mandatory in order to avoid excess CLT dosing,
which could lead to low-dynamic metabolic bone disease [34].
Studies are currently underway in our center to identify the lowest
i.v. CLT dose required to maintain this state of euparathyroidism,
once the hyperparathyroidism has been reversed.
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